News & Events about Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Arcturus Therapeutics, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today...
Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the...
Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that is has...
CSL Announces Closing of Global Collaboration and Licensing Agreement with Arcturus Therapeutics CSL Announces Closing of Global Collaboration and Licensing Agreement with Arcturus Therapeutics PR Newswire KING OF PRUSSIA, Pa., Dec. 12, 2022 CSL to access late-stage next-generation mRNA platform...
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT Get Rating) HC Wainwright raised their Q3 2023 EPS estimates for Arcturus Therapeutics in a report issued on Thursday, November 10th. HC Wainwright analyst E. Arce now expects that the biotechnology company will post earnings per share of $0.11 for ...